VIVO BIO TECH LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.57 INR | -0.62% |
|
-1.09% | +34.65% |
| Sales 2022 | 514M 6.16M 491M | Sales 2023 | 522M 6.26M 499M | Capitalization | 288M 3.45M 275M |
|---|---|---|---|---|---|
| Net income 2022 | 22M 264K 21.02M | Net income 2023 | 26M 312K 24.84M | EV / Sales 2022 | 2.38 x |
| Net Debt 2022 | 657M 7.88M 628M | Net Debt 2023 | 610M 7.31M 583M | EV / Sales 2023 | 1.72 x |
| P/E ratio 2022 |
25.5
x | P/E ratio 2023 |
10.8
x | Employees | 150 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 26.6% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.62% | ||
| 1 week | -1.09% | ||
| Current month | -1.81% | ||
| 1 month | -3.47% | ||
| 3 months | +4.11% | ||
| 6 months | +28.52% | ||
| Current year | +34.65% |
1 week
44.00
46.50
1 month
43.0050.80
Current year
32.0056.00
1 year
21.0556.00
3 years
18.11115.10
5 years
17.50115.10
10 years
15.10115.10
| Managers | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | 44 | 02/11/21 | |
| Director/Board Member | 80 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | 44 | 02/11/21 | |
N. Kalpana Kunda
CHM | Chairman | 41 | 29/06/20 |
| Director/Board Member | 45 | 28/07/16 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/05/24 | 44.57 | -0.62% | 14,220 |
| 02/05/24 | 44.85 | -1.19% | 29,146 |
| 30/04/24 | 45.39 | +2.41% | 21,709 |
| 29/04/24 | 44.32 | -1.64% | 34,391 |
| 26/04/24 | 45.06 | -0.24% | 12,591 |
Delayed Quote Bombay S.E., May 03, 2024 at 11:00 am
More quotes
Vivo Bio Tech Limited is a comprehensive pre-clinical clinical research organization (CRO) providing drug development and discovery services company. It operates in biotechnology segment. The Company offering drug development and discovery services to pharmaceutical and biotech companies. The Company offers services in the areas of in vivo and in vitro toxicity studies, pharmacological investigations, pharmacokinetic and toxic kinetic studies, genotoxicity screening, and analytical services. It provides both regulatory and non-regulatory IND enabling preclinical development services. The Company provides screening and evaluating molecules for various pharmacological and therapeutic properties. Specifically for oncology, it provides design and development of syngeneic / xenograft models for evaluation of anti-cancer agent. The Company also customizes In vivo drug metabolism and pharmacokinetics (DMPK) studies to help profile drug candidate in both rodent and non-rodent animal models.
Calendar
26/05/2024
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +34.65% | 7.97M | |
| +25.69% | 47.86B | |
| +46.90% | 41.42B | |
| -3.46% | 40.66B | |
| -6.20% | 28.92B | |
| +9.17% | 25.55B | |
| -20.42% | 19.27B | |
| +28.07% | 12.14B | |
| +0.17% | 12.15B | |
| -1.24% | 11.99B |
- Stock Market
- Equities
- VIVOBIOT6 Stock
